Article Text

PDF
Methylphenidate hydrochloride reduces hyperactivity in children with pervasive development disorders

Statistics from Altmetric.com


 
 Q Does methylphenidate hydrochloride reduce hyperactivity and impulsiveness in children with pervasive development disorder?

METHODS

Embedded ImageDesign:

Crossover randomised controlled trial.

Embedded ImageAllocation:

Concealed.

Embedded ImageBlinding:

Double blind.

Embedded ImageFollow up period:

Four weeks.

Embedded ImageSetting:

Five university outpatient centres, USA; recruitment November 2001 to September 2003.

Embedded ImagePatients:

Sixty six children (89% male) aged 5–14 years with DSM-IV autism, Asperger’s syndrome, or unidentified pervasive development disorder plus hyperactivity and/or impulsiveness for ⩾6 months with onset before age 7. Exclusions: receiving psychotropic medication in previous 1–3 weeks; mental age <18 months; other neuropsychiatric disorders; moderate or severe tic disorder; seizures in the past six months; hypertension; other serious medical comorbidity; methylphenidate treatment in previous two years; previous adverse reaction to methylphenidate or adverse reaction to during tolerability testing.

Embedded ImageIntervention:

Placebo followed by low dose methylphenidate (0.125 mg/kg), medium dose methylphenidate (0.25 mg/kg), or high …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.